Dyne and Sarepta shares slump as Novartis trial setback hits muscle disease stocks
Shares of Dyne Therapeutics (DYN) and Sarepta (SRPT) fell Tuesday after Novartis’ NOT treatment for a muscle-wasting disorder failed in a trial, raising concerns about similar therapies for a rare disease.
By Sriparna RoyShares of Dyne Therapeutics NASDAQ:DYN and Sarepta NASDAQ:SRPT slumped on Tuesday after Novartis' BX:NOT treatment for a muscle-wasting disorder failed in a trial, fueling investor concerns about the prospects of similar therapies for the tough-to-treat rare disease.Dyne's stock led…